<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Sorafenib combination therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/sorafenib-combination-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 09 Sep 2025 04:44:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Sorafenib combination therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Boosting Sorafenib Efficacy via Dipeptidyl Peptidase 9 Inhibition</title>
		<link>https://bioengineer.org/boosting-sorafenib-efficacy-via-dipeptidyl-peptidase-9-inhibition/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 09 Sep 2025 04:43:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[DPP9 inhibition cancer therapy]]></category>
		<category><![CDATA[Ferroptosis induction in HCC]]></category>
		<category><![CDATA[Liver cancer treatment resistance]]></category>
		<category><![CDATA[Oxidative cell death mechanisms]]></category>
		<category><![CDATA[Sorafenib combination therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/boosting-sorafenib-efficacy-via-dipeptidyl-peptidase-9-inhibition/</guid>

					<description><![CDATA[Recent advances in the understanding of hepatocellular carcinoma (HCC), a prevalent form of liver cancer, have highlighted the need for more effective therapeutic strategies to counter its aggressive nature and resistance to standard treatments. Sorafenib, a first-line oral multikinase inhibitor, has been the cornerstone of systemic therapy for advanced HCC. However, its effectiveness is often [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">267722</post-id>	</item>
	</channel>
</rss>
